BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer. Rome Therapeutics Inc. launched...
BC Innovations | Feb 24, 2020
Distillery Therapeutics

DICER1 gene therapy for choroidal neovascularization

DISEASE CATEGORY: Ophthalmic INDICATION: Choroidal neovascularization (CNV) An adeno-associated viral serotype 2 (AAV2)-based gene therapy delivering the RNase DICER1 could treat CNV. In mice with spontaneous CNV, subretinal injection of an AAV2 vector encoding a...
BC Extra | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

Three women were appointed this week to C-suite positions at biotechs with valuations over $1 billion. The hires come the same week as a report from BIO that found that about 30% of biotech executives...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Innovations | Aug 22, 2018
Translation in Brief

Confirming CRISPR

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening...
BC Extra | Jul 16, 2018
Preclinical News

On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology....
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Innovations | Jul 25, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five...
BC Week In Review | Jul 14, 2017
Clinical News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) said FDA would no longer require an additional Phase III study of migalastat (AT1001) to treat Fabry's disease, clearing the way for the company to submit an NDA...
BC Extra | Jul 12, 2017
Company News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) gained $2.66 (26%) to $12.92 on Tuesday after it said FDA would no longer require an additional Phase III study of migalastat ( AT1001 ) to treat Fabry's disease, clearing...
Items per page:
1 - 10 of 151
BioCentury | Apr 29, 2020
Emerging Company Profile

Rome: tackling repeat DNA for cancer, autoimmunity

GV-incubated Rome joins a growing cadre of companies targeting repeat biology, with plans to suppress repeat DNA-induced innate immune responses to treat autoimmune disorders and activate the same pathways for cancer. Rome Therapeutics Inc. launched...
BC Innovations | Feb 24, 2020
Distillery Therapeutics

DICER1 gene therapy for choroidal neovascularization

DISEASE CATEGORY: Ophthalmic INDICATION: Choroidal neovascularization (CNV) An adeno-associated viral serotype 2 (AAV2)-based gene therapy delivering the RNase DICER1 could treat CNV. In mice with spontaneous CNV, subretinal injection of an AAV2 vector encoding a...
BC Extra | Feb 1, 2020
Company News

Management tracks: Trio of female exec appointments; plus FDA, Cell and Gene Therapy Catapult, SutroVax, Lundquist Institute, RedShift, NeoImmuneTech and more

Three women were appointed this week to C-suite positions at biotechs with valuations over $1 billion. The hires come the same week as a report from BIO that found that about 30% of biotech executives...
BioCentury | Oct 17, 2019
Emerging Company Profile

Parker Institute’s ArsenalBio launches with $85M to build cell engineering war chest

ArsenalBio launched Thursday with $85 million in a series A round to combine the technologies of its six Parker Institute co-founders into a suite of tools the company thinks could overcome key hurdles to cell...
BC Innovations | Aug 22, 2018
Translation in Brief

Confirming CRISPR

Two critiques of a 2017 human embryo gene editing study, including one suggesting large deletions at the target site misled researchers into thinking CRISPR-Cas9 corrected a genetic mutation, raise questions about what assays and screening...
BC Extra | Jul 16, 2018
Preclinical News

On-target mutations latest worry for CRISPR stocks

On the heels of preclinical studies evaluating off-target mutations driven by CRISPR-Cas9 gene editing, geneticist Allan Bradley’s group from the Wellcome Sanger Institute shifted the spotlight to on-target mutations that could result from the technology....
BioCentury | May 18, 2018
Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
BC Innovations | Jul 25, 2017
Distillery Therapeutics

Infectious disease

INDICATION: HIV / AIDS Macaque studies suggest adding a boost containing five HIV gp120 variants to HIV vaccine regimens could help prevent infection by the virus. The boost consists of the adjuvant GLA-SE and five...
BC Week In Review | Jul 14, 2017
Clinical News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) said FDA would no longer require an additional Phase III study of migalastat (AT1001) to treat Fabry's disease, clearing the way for the company to submit an NDA...
BC Extra | Jul 12, 2017
Company News

FDA clears Amicus to submit migalastat NDA without new trial

Rare disease company Amicus Therapeutics Inc. (NASDAQ:FOLD) gained $2.66 (26%) to $12.92 on Tuesday after it said FDA would no longer require an additional Phase III study of migalastat ( AT1001 ) to treat Fabry's disease, clearing...
Items per page:
1 - 10 of 151